Guanglin Luo

USPTO Granted Patents = 41 (Patent Applications = 2)

CIPO Patents = 1 (Patent Applications = 5)

EPO Patents = 16 (Patent Applications = 10)

Average Co-Inventor Count = 4.3

ph-index = 10

Forward Citations = 211(Granted Patents)

Location History:

Providence, RI (US) (2000 - 2004)
Newton, PA (US) (2019)
Madison, CT (US) (2001 - 2023)
Newtown, PA (US) (2018 - 2024)

Company Filing History:

31 out of 3,681

Bristol-myers Squibb Compnay

patents

3 out of 5,303

Leland Stanford Junior University

Bristol-meyers Squibb

patent

5. 1 out of 41

Bristol Meyers Squibb Company

patents

6. 1 out of 7

Syngene International Limited

patents

7. 6 out of 832,680

Other

patents

where one patent can have more than one assignee

Years Active: 2000-2024

Loading Chart...

41 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 12172975 - 1H-indazole carboxamides as receptor-interacting protein kinase 1 inhibitors (RIPK1) (2024-12-24),

2. 12157733 - Aminotriazolopyridines as kinase inhibitors (2024-12-03),

3. 12110290 - Triazolopyridinyl compounds as kinase inhibitors (2024-10-08),

4. 12065437 - Biaryl kinase inhibitors (2024-08-20),

5. 11767322 - Triazolopyridinyl compounds as kinase inhibitors (2023-09-26),

6. 11618753 - Aminopyrrolotriazines as kinase inhibitors (2023-04-04),

7. 11440913 - Aminoimidazopyridazines as kinase inhibitors (2022-09-13),

8. 11053258 - Pyrimidine carboxamides as GSK-3 inhibitors (2021-07-06),

9. 10981910 - Biaryl kinase inhibitors (2021-04-20),

10. 10913738 - Aminotriazolopyridines as kinase inhibitors (2021-02-09),

11. 10752609 - GSK-3 inhibitors (2020-08-25),

12. 10723734 - Biaryl kinase inhibitors (2020-07-28),

13. 10550080 - Acyl sulfonamide NaV1.7 inhibitors (2020-02-04),

14. 10544120 - Biaryl kinase inhibitors (2020-01-28),

15. 10351563 - Biaryl kinase inhibitors (2019-07-16),

Title: Guanglin Luo: A Pioneering Inventor in the Field of Kinase Modulation

Introduction:

Guanglin Luo, a remarkable inventor based in Madison, CT, is a trailblazer in the realm of kinase modulation. With an impressive portfolio of 37 patents to his name, Luo's dedication to innovation has set him apart as a visionary in the field of pharmaceutical research and development.

Latest Patents:

Luo's latest patents showcase his expertise in developing cutting-edge compounds for kinase modulation. One of his recent inventions includes Triazolopyridinyl compounds as kinase inhibitors, which have shown promise in modulating RIPK1. Additionally, his Aminopyrrolotriazines as kinase inhibitors offer new avenues for treatments related to necrosis, inflammation, and various other indications.

Career Highlights:

Having worked with prestigious companies like Bristol-Myers Squibb Company, Guanglin Luo has honed his skills and knowledge in the pharmaceutical industry. His contributions to the field have been instrumental in advancing the understanding of kinase modulation and its potential therapeutic applications.

Collaborations:

Throughout his career, Luo has collaborated with esteemed professionals such as John E. Macor and Ling Chen. These collaborations have not only enriched his work but have also led to the development of innovative solutions that have the potential to revolutionize the pharmaceutical landscape.

Conclusion:

In conclusion, Guanglin Luo stands as a shining example of an inventor whose passion for innovation knows no bounds. His relentless pursuit of excellence and commitment to pushing the boundaries of what is possible continue to inspire the next generation of inventors and innovators.

This text is generated by artificial intelligence and may not be accurate.